Business Context and Reporting Period
This Form 6-K filing by Mereo Biopharma Group Plc (Mereo) is dated June 13, 2019. Mereo is a clinical-stage biopharmaceutical company focused on rare diseases. The filing primarily addresses a strategic update regarding the etigilimab (anti-TIGIT) program, which was acquired through Mereo's April 2019 merger with OncoMed Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide specific financial statements, revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. The document focuses on corporate developments and clinical trial status rather than financial performance metrics.
Material Changes
- Termination of Celgene Partnership: Celgene Corporation notified OncoMed (a Mereo subsidiary) of its decision not to exercise its option to license etigilimab due to strategic product portfolio considerations.
- Retention of Rights: Mereo expects to retain worldwide rights to etigilimab upon the termination of the Collaboration Agreement and plans to initiate discussions with other potential partners.
- Impact on Contingent Value Rights (CVRs): Holders of CVRs under the April 23, 2019, and March 14, 2019 agreements will not be entitled to receive the TIGIT Milestone Payment or TIGIT Payment Amounts, respectively, as a consequence of the agreement termination.
Guidance, Outlook, and Management Commentary
Management Commentary: CEO Denise Scots-Knight stated that while Mereo prioritizes its rare disease portfolio (setrusumab and alvelestat), the anti-TIGIT program remains a promising immuno-oncology approach. The company respects Celgene's decision and looks forward to partnering discussions for etigilimab and other non-rare disease assets (acumapimod, navicixzumab, leflutrozole).
Clinical Outlook:
- Etigilimab: Phase 1a dose-escalation is complete with no dose-limiting toxicities observed at the recommended Phase 2 dose of 20mg/kg Q2W. The Phase 1b combination study with nivolumab is fully enrolled and in the safety monitoring phase.
- Setrusumab (OI): Phase 2b enrollment of 112 adults is complete; 12-month data expected in Q4 2019. Pediatric Phase 3 design approved by EMA.
- Alvelestat (AATD): First patient dosed in Phase 2 U.S. study; data expected end of 2019.
- Acumapimod (COPD): Pivotal Phase 3 study outline announced following FDA Type B meeting.
- Navicixizumab: Phase 1b trial in platinum-resistant ovarian cancer has completed enrollment.
Risks and Contingencies: The primary risk highlighted is the loss of the Celgene partnership and the associated milestone payments for CVR holders. The company faces the contingency of securing a new partner for etigilimab to advance the program.
Investor Verification Checklist
- Verify the specific terms of the terminated Collaboration Agreement regarding any potential termination fees or retained rights.
- Confirm the timeline for the release of Phase 1b data for etigilimab in combination with nivolumab.
- Monitor announcements regarding new partnership discussions for etigilimab and other non-rare disease assets.
- Review upcoming financial reports to assess the cash burn rate and liquidity position following the loss of expected milestone payments.
- Track the Q4 2019 release of top-line 12-month data for setrusumab.